Mapping the breast tumor microenvironment: proximity analysis reveals spatial relationships between macrophage subtypes and metastasis-initiating cancer cells
- PMID: 39164522
- PMCID: PMC12268993
- DOI: 10.1038/s41388-024-03127-9
Mapping the breast tumor microenvironment: proximity analysis reveals spatial relationships between macrophage subtypes and metastasis-initiating cancer cells
Abstract
Metastasis is responsible for the majority of cancer-related fatalities. We previously identified specific cancer cell populations responsible for metastatic events which are cytokeratin-14 (CK14) and E-cadherin positive in luminal tumors, and E-cadherin and vimentin positive in triple-negative tumors. Since cancer cells evolve within a complex ecosystem comprised of immune cells and stromal cells, we sought to decipher the spatial interactions of these aggressive cancer cell populations within the tumor microenvironment (TME). We used imaging mass cytometry to detect 36 proteins in tumor microarrays containing paired primary and metastatic lesions from luminal or triple-negative breast cancers (TNBC), resulting in a dataset of 1,477,337 annotated cells. Focusing on metastasis-initiating cell populations, we observed close proximity to specific fibroblast and macrophage subtypes, a relationship maintained between primary and metastatic tumors. Notably, high CK14 in luminal cancer cells and high vimentin in TNBC cells correlated with close proximity to specific macrophage subtypes (CD163intCD206intPDL1intHLA-DR+ or PDL1highARG1high). Our in-depth spatial analysis demonstrates that metastasis-initiating cancer cells consistently colocalizes with distinct cell populations within the TME, suggesting a role for these cell-cell interactions in promoting metastasis.
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
COMPETING INTERESTS
AJE is a consultant for BioNTech, has unlicensed patents on biomarkers for cancer and on the use of antibodies as anti-cancer therapeutics, and his spouse is an employee of Immunocore. WJH reports patent royalties from Rodeo/Amgen, received grants from Sanofi and NeoTX (to Johns Hopkins), and speaking/travel honoraria from Exelixis and Standard BioTools. AC-M has received research grants from HeritX, Genentech, and Bristol Myers Squibb (to Johns Hopkins) and previously served as a consultant to Bristol Myers Squibb.
Figures





References
-
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA A Cancer J Clin. 2022;72:7–33. - PubMed
MeSH terms
Substances
Grants and funding
- 23-048/Breast Cancer Research Foundation (BCRF)
- R21CA264004/U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
- U01CA284090/U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
- U54 CA268083/CA/NCI NIH HHS/United States
- P30CA006973/U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous